本文采用的英格恩产品: RNA-Entranster-invivo
Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism
Affiliations
- 1 Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Road, Shanghai, 200025, P. R. China.
- 2 State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Road, Shanghai, 200025, P. R. China.
- 3 Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Road, Shanghai, 200025, P. R. China.
- 4 Research Institute of Pancreatic Diseases, Shanghai Key Laboratory of Translational Research for Pancreatic Neoplasms, Shanghai Jiaotong University School of Medicine, 227 South Chongqing Road, Shanghai, 200025, P. R. China.
- 5 Precision Immunotherapy, Graduate Institute of Biomedical Sciences, China Medical University, No. 91, Xueshi Road, Taichung, 404, Taiwan.
- 6 Immunology Research and Development Center, China Medical University, No. 91, Xueshi Road, Taichung, 404, Taiwan.
- 7 Pancreatic Cancer Heterogeneity, Candiolo Cancer Institute – FPO – IRCCS, Strada Provinciale 142 Km 3,95, Candiolo (TO), 10060, Italy.
- 8 School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai, 200237, P. R. China.
- 9 Department of Pathology, Candiolo Cancer Institute – FPO – IRCCS, Strada Provinciale 142 Km 3,95, Candiolo (TO), 10060, Italy.
- PMID: 39297408
- DOI: 10.1002/advs.202308990
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic and lethal disease. Gasdermins are primarily associated with necrosis via membrane permeabilization and pyroptosis, a lytic pro-inflammatory type of cell death. In this study, GSDMC upregulation during PDAC progression is reported. GSDMC directly induces genes related to stemness, EMT, and immune evasion. Targeting Gsdmc in murine PDAC models reprograms the immunosuppressive tumor microenvironment, rescuing the recruitment of anti-tumor immune cells through CXCL9. This not only results in diminished tumor initiation, growth and metastasis, but also enhances the response to KRASG12D inhibition and PD-1 checkpoint blockade, respectively. Mechanistically, it is discovered that ADAM17 cleaves GSDMC, releasing nuclear fragments binding to promoter regions of stemness, metastasis, and immune evasion-related genes. Pharmacological inhibition of GSDMC cleavage or prevention of its nuclear translocation is equally effective in suppressing GSDMC’s downstream targets and inhibiting PDAC progression. The findings establish GSDMC as a potential therapeutic target for enhancing treatment response in this deadly disease.
Keywords: KRAS inhibition; cancer stem cells; gasdermin C; immune evasion; immunotherapy; invasion; metastasis; pancreatic ductal adenocarcinoma.